Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
167 SAR | +0.72% | +3.47% | -2.79% |
Mar. 20 | Dallah Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 14 | Dallah Healthcare Logs Higher FY23 Net Profit, Revenue | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 41.93 and 31.29 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.79% | 4.32B | - | ||
-18.90% | 16.51B | B+ | ||
+4.50% | 12.53B | B | ||
+4.81% | 11.74B | B+ | ||
+2.43% | 10.06B | B+ | ||
-4.75% | 7.57B | A- | ||
+19.68% | 7.22B | D | ||
+5.46% | 6.68B | B- | ||
+45.72% | 4.54B | - | ||
-5.47% | 4.17B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4004 Stock
- Ratings Dallah Healthcare Company